Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes.

26 , 27 While one study found no consistent trend for risk of pancreatitis with DPP-4 inhibitors, 28 other meta-analyses observed a positive trend towards increased risk for pancreatitis with DPP-4 inhibitors. 29 , 30 With GLP-1 receptor agonists, liraglutide 1.8 mg-treated patients with T2DM showed a 28% increase in serum lipase levels and a 7% increase in serum amylase levels compared with the placebo group, in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial. 4 During this trial, 0.4% of liraglutide-treated and 0.5% of placebo patients developed AP.

also in 11,005 other papers

LIVER DISEASE Individual patient‐level data meta‐analysis of the Liraglutide Effect and Action in Diabetes program suggested that treatment with 1.8 mg of liraglutide significantly reduced alanine aminotransferase in patients with T2DM and abnormal baseline alanine aminotransferase and showed a trend towards improving hepatic steatosis. 9 Studies suggest that in patients with non-alcoholic steatohepatitis, particularly those with diabetes, GLP-1 receptor agonists (including 0.9 and 1.8 mg of liraglutide) may improve liver histology and reduce aminotransferase levels from baseline. 10 Animal stu

also in 53,322 other papers